MX2018002849A - Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos. - Google Patents

Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.

Info

Publication number
MX2018002849A
MX2018002849A MX2018002849A MX2018002849A MX2018002849A MX 2018002849 A MX2018002849 A MX 2018002849A MX 2018002849 A MX2018002849 A MX 2018002849A MX 2018002849 A MX2018002849 A MX 2018002849A MX 2018002849 A MX2018002849 A MX 2018002849A
Authority
MX
Mexico
Prior art keywords
cd45rclow
tregs
new subpopulation
subpopulation
new
Prior art date
Application number
MX2018002849A
Other languages
English (en)
Inventor
Bezie Séverine
Anegon Ignacio
Guillonneau Carole
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2018002849A publication Critical patent/MX2018002849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

La invención se refiere a una nueva subpoblación de Tregs CD8+CD45RCbajo, principalmente una población de células Treg CD8+CD45RCbajo que secretan IFN?+IL-10+IL-34+, métodos para su aislamiento y expansión y su uso como fármaco, más particularmente para inmunoterapia así como biomarcador.
MX2018002849A 2015-09-07 2016-09-06 Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos. MX2018002849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306366 2015-09-07
PCT/EP2016/070991 WO2017042170A1 (en) 2015-09-07 2016-09-06 A new subpopulation of cd8+cd45rclow tregs and uses thereof

Publications (1)

Publication Number Publication Date
MX2018002849A true MX2018002849A (es) 2018-09-05

Family

ID=54196910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002849A MX2018002849A (es) 2015-09-07 2016-09-06 Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.

Country Status (13)

Country Link
US (1) US20180251731A1 (es)
EP (1) EP3347452B1 (es)
JP (2) JP2018527932A (es)
KR (1) KR20180054663A (es)
CN (1) CN108291203A (es)
AU (1) AU2016318762B2 (es)
BR (1) BR112018004454A2 (es)
CA (1) CA2997646C (es)
ES (1) ES2890818T3 (es)
IL (1) IL257891B (es)
MX (1) MX2018002849A (es)
WO (1) WO2017042170A1 (es)
ZA (1) ZA201801265B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056406A1 (en) 2017-03-15 2018-09-20 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
EP3652306A1 (en) * 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
EP3740569B1 (en) * 2018-01-19 2023-07-26 Miltenyi Biotec B.V. & Co. KG Regulatory t cell expressing a chimeric antigen receptor
CA3090175A1 (en) 2018-02-08 2019-08-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for allogenic hematopoietic stem cell transplantation
EP3765121A4 (en) * 2018-03-14 2021-12-22 Thermogenesis Corp. ACTIVATION / TRANSDUCTION SYSTEMS AND PROCEDURES COMPATIBLE WITH BUILD-UP ACTIVATED CELL SORTING (BACS)
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
US20220064260A1 (en) 2018-12-14 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
WO2020223568A1 (en) * 2019-04-30 2020-11-05 The Regents Of The University Of California Bead-free ex-vivo expansion of human regulatory t cells
WO2024028486A1 (en) * 2022-08-04 2024-02-08 Nantes Universite In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077299A2 (en) * 2000-04-11 2001-10-18 University Of Southern California A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
LT2126054T (lt) * 2007-01-31 2016-10-10 Yeda Research And Development Company Limited Peradresuotos, genetiškai modifikuotos t reguliavimo ląstelės ir jų naudojimas autoimuninės ir uždegiminės ligos slopinimui
JP2017516752A (ja) * 2014-04-01 2017-06-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 単離されたドナーｍｈｃ由来ペプチド及びその使用
ES2710444T3 (es) * 2014-07-17 2019-04-25 Inst Nat Sante Rech Med Un polipéptido de interleucina 34 aislado para uso en la prevención del rechazo de trasplante y el tratamiento de enfermedades autoinmunitarias

Also Published As

Publication number Publication date
BR112018004454A2 (pt) 2018-09-25
JP2021183631A (ja) 2021-12-02
CA2997646C (en) 2024-04-23
JP7254128B2 (ja) 2023-04-07
AU2016318762A1 (en) 2018-03-22
US20180251731A1 (en) 2018-09-06
EP3347452B1 (en) 2021-06-23
ES2890818T3 (es) 2022-01-24
CA2997646A1 (en) 2017-03-16
RU2766691C2 (ru) 2022-03-15
IL257891A (en) 2018-05-31
AU2016318762B2 (en) 2022-03-31
KR20180054663A (ko) 2018-05-24
RU2018107363A3 (es) 2020-02-27
JP2018527932A (ja) 2018-09-27
IL257891B (en) 2020-09-30
CN108291203A (zh) 2018-07-17
RU2018107363A (ru) 2019-10-09
EP3347452A1 (en) 2018-07-18
WO2017042170A1 (en) 2017-03-16
ZA201801265B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
MX2018002849A (es) Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
PH12018500947A1 (en) Crystal form, preparation method and intermediate of dihydropyrido ring compound
PH12017500441A1 (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
PH12017502255A1 (en) Nrf2 regulators
GB2570593A (en) Methods relating to intestinal organ-on-a-chip
MX2022006513A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
IL248451A0 (en) Methods for the isolation, culture and genetic engineering of immune cell populations for stress therapy
EP4272746A3 (en) Crystal forms of beta-nicotinamide mononucleotide
EP3356526A4 (en) COMPREHENSIVE IN-VITRO MESSAGE OF CREATING EVENTS BY SEQUENCING (CIRCLE-SEQ)
MA39819A (fr) Méthodes et compositions d'immunomodulation
MX2019006539A (es) Sistemas y metodos para la extraccion de productos naturales.
TWD178825S (zh) 項鍊
MX2019001313A (es) Composiciones farmaceuticas.
MY176746A (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
TWD176021S (zh) 項鍊
MY191539A (en) Streptococcal vaccine
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
EP4285930A3 (en) Protein formulations
MX2020002793A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.